2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148763
    CK2-IN-6 1309835-18-4 98%
    CK2-IN-6 is a potent protein kinase CK2 inhibitor that can be used in the study of cancer as well as other kinase-related conditions, including inflammation, pain and certain immune diseases.
    CK2-IN-6
  • HY-148768
    AB-506 2245020-50-0 98%
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research.
    AB-506
  • HY-148806
    Zatonacaftor 2301945-38-8 98%
    Zatonacaftor is a modulator of cystic fibrosis transmembrane regulator (CFTR) protein. Zatonacaftor can be used for research of cystic fibrosis.
    Zatonacaftor
  • HY-148832
    BTK-IN-20 1581714-50-2 98%
    BTK-IN-20 (compound 283) is a BTK tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation.
    BTK-IN-20
  • HY-148862
    Cavα2δ1&NET-IN-1 2314361-39-0 98%
    Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Cavα2δ-1 with a Ki of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a Ki of 383 nM and IC50 of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain.
    Cavα2δ1&NET-IN-1
  • HY-148863
    Cavα2δ1&NET-IN-2 2143586-17-6 98%
    Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Cavα2δ-1 with a Ki of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a Ki of 59 nM and IC50 of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain.
    Cavα2δ1&NET-IN-2
  • HY-148936
    GLX481372 1990478-58-4 98%
    GLX481372 is a NADPH Oxidase (NOX) inhibitor. GLX481372 potently inhibits NOX4/5 activities with IC50 values of 0.68 and 0.57 μM. GLX481372 also has weak inhibitory activity against NOX1, NOX2, and NOX3, with IC50 values of 7, 16 and 3.2 μM respectively. GLX481372 can inhibit ROS production. GLX481372 can be used for the researches of inflammation, cardiovascular and metabolic disease, such as diabetes.
    GLX481372
  • HY-149025
    DPTIP-prodrug 18 2881068-33-1 98%
    DPTIP-proagent 18 (P18) is a orally active and brain-penetrable proagent of DPTIP (HY-131002). DPTIP-proagent 18 is a potent nSMase2 inhibitor. DPTIP-proagent 18 significantly inhibits IL-1β-induced EV (extracellular vesicle) release by inhibition of nSMase2 (neutral sphingomyelinase-2) activity. DPTIP-proagent 18 can be used for brain injury research.
    DPTIP-prodrug 18
  • HY-149052
    SZM-1209 2919801-86-6 98%
    SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects.
    SZM-1209
  • HY-149082
    LTB4 antagonist 1 2929239-84-7 98%
    LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties.
    LTB4 antagonist 1
  • HY-149083
    LTB4 antagonist 2 2929239-85-8 98%
    LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM.
    LTB4 antagonist 2
  • HY-149084
    LTB4 antagonist 3 2929239-87-0 98%
    LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist with an IC50 value of 477 nM. LTB4 antagonist 3 has anti-inflammatory activity.
    LTB4 antagonist 3
  • HY-149087
    MR2938 1044870-65-6 98%
    MR2938 is a potent AChE inhibitor, with an IC50 of 5.04 μM. MR2938 also suppresses NO production obviously (IC50 = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.
    MR2938
  • HY-149101
    Inosine-5'-diphosphate 86-04-4 98%
    Inosine-5'-diphosphate (IDP) is a decoy substrate of NM23-H2. Inosine-5'-diphosphate has a superior bond capacity on GDP-binding pocket of NM23-H2 (KD: 5.0 μM). Inosine-5'-diphosphate abrogates c-MYC transcription, induces apoptosis and G2/M cell cycle arrest by disrupting NM23-H2-Pu27-GQ interactions without affecting NM23-H2-mediated kinase properties. Inosine-5'-diphosphate has antihypoxic, antihyperthermic and antiarrhythmic activity and protects animals against the noxious effects of γ-irradiation. Inosine-5'-diphosphate can be used for cancers like Burkitt's lymphoma and cardiovascular diseases research.
    Inosine-5'-diphosphate
  • HY-149102
    LE 28 1416080-97-1 98%
    LE 28 is a selective and activity-dependent legumain probe. LE 28 becomes fluorescent only upon binding active legumain. LE 28 can be used for research of cancers and inflammatory diseases.
    LE 28
  • HY-149121
    NLRP3-IN-14 2767369-80-0 98%
    NLRP3-IN-14 is a potent and selective NLRP3 inflammasome inhibitor (KD: 5.87 μM). NLRP3-IN-14 inhibits IL-1β release with an IC50 of 0.131 μM. NLRP3-IN-14 can be used for the research of inflammation.
    NLRP3-IN-14
  • HY-149122
    NLRP3-IN-15 2767369-71-9 98%
    NLRP3-IN-15 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-15 inhibits IL-1β release with an IC50 of 0.114 μM. NLRP3-IN-15 can be used for the research of inflammation.
    NLRP3-IN-15
  • HY-149123
    NLRP3-IN-16 2906872-59-9 98%
    NLRP3-IN-16 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-16 inhibits IL-1β release with an IC50 of 0.065 μM. NLRP3-IN-16 can be used for the research of inflammation.
    NLRP3-IN-16
  • HY-149151
    Variegatic acid 20988-30-1 98%
    Variegatic acid is a secondary metabolite derived from basidiomycete fungi. Variegatic acid is a PKCβ1 inhibitor with an IC₅₀ of 36.2 μM. Variegatic acid inhibits antigen- or calcium ionophore-induced β-hexosaminidase release (IC₅₀ values of 10.4 μM and 22.2 μM, respectively) and TNF-α secretion (IC₅₀ values of 16.8 μM and 20.1 μM, respectively). Variegatic acid suppresses the enzymatic activity of calcium-activated PKCβ1 and reduces Fe(III) to Fe(II) in a pH-dependent manner, enabling the generation of hydroxyl radicals (·OH) through reaction with H₂O₂, which facilitates the degradation of lignocellulose. Variegatic acid is useful for studying biological degradation and allergic responses.
    Variegatic acid
  • HY-149165
    Glucocorticoid receptor modulator 2 2452396-89-1 99.84%
    Glucocorticoid receptor modulator 2 (Example 1) is a glucocorticoid receptor modulator, with an IC50 value less than 100 nM. Glucocorticoid receptor modulator 2 can be used for research of inflammatory and immune diseases.
    Glucocorticoid receptor modulator 2
Cat. No. Product Name / Synonyms Application Reactivity